Throughout February 2026, Revvity proudly reinforces its leadership in newborn screening by shining a light on rare diseases, conditions that affect millions of individuals and families worldwide. Although often considered uncommon, rare diseases collectively represent a significant global health challenge. Our longstanding commitment to newborn screening reflects our belief in the power of early detection and timely intervention to improve outcomes and quality of life for affected children and their families.
Rare diseases, sometimes referred to as orphan diseases, are typically defined as conditions affecting a small proportion of the population, often fewer than 1 in 2,000 individuals. Definitions vary by region, but the challenges associated with rare diseases are universal. Thousands of distinct rare conditions exist, many of them genetic in origin, each presenting unique clinical features and complexities.
Because of their rarity and diversity, these conditions frequently present diagnostic challenges. Delayed or incorrect diagnoses are common, prolonging uncertainty for families and delaying access to appropriate care. This underscores the critical importance of early identification, an area where newborn screening plays a vital role.
While each rare disease may affect relatively few individuals, together they impact millions of people globally. Raising awareness and expanding understanding are essential steps in ensuring that affected individuals receive timely support, appropriate care, and access to emerging therapies.
Our newborn screening solutions support the early identification of conditions that may otherwise go undetected at birth. By enabling healthcare professionals to identify relevant biomarkers shortly after delivery, newborn screening helps facilitate earlier clinical follow-up and informed care decisions.
Revvity believes that newborn screening should be accessible to all.
Reflecting on our progress and future direction, Anna Godenhjelm, General Manager of Revvity’s reproductive health business, shares:
“I am deeply inspired by Revvity’s ongoing dedication to advancing newborn screening worldwide. We are focused on developing innovative technologies that address today’s screening challenges while anticipating the needs of the future."
"Through research, strategic partnerships, and collaboration, we are exploring how next-generation sequencing can transform newborn screening, not just in testing, but also in digital solutions and data management. Our recent developments with software designed to digitize handwritten DBS cards, along with the emerging potential of AI-powered systems to help labs operate faster and more efficiently at scale, is truly exciting as we move through 2026.”
This February, we honor the strength and resilience of individuals and families living with rare diseases and reaffirm the importance of awareness, education, and early detection. Revvity’s evolving portfolio of screening technologies continues to support healthcare systems in identifying conditions earlier helping to improve care pathways and outcomes.
As a global leader in newborn screening, Revvity recognizes the responsibility that comes with enabling early, informed decision-making for population screening programs. Beyond technology, we actively collaborate with healthcare professionals, researchers, and advocacy organizations to support a more connected and comprehensive approach to rare disease management.
Join us this Rare Disease Awareness Month, and on Rare Disease Day - February 28, as we stand alongside the global community in raising awareness and advancing early detection. Together, we can help shape a healthier future for individuals and families affected by rare diseases.
Revvity does not endorse or make recommendations regarding specific research, medications, or treatments. All information provided is for informational purposes only and is not intended as medical advice.
